Author: Noel Lloyd
Date: September 18th, 2015
On September 16 the ACT-AD (Accelerate Cure/Treatments for Alzheimer's Disease) Coalition hosted its Eighth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease therapeutic development with representatives from the U.S. Food and Drug Administration, researchers, and other interested stakeholders.
This year’s meeting, centered on the theme of “Assessing the Scientific Foundation for Alzheimer’s Disease Therapeutic Development,” focused on what researchers need to do to improve prospects for Alzheimer’s disease treatment and prevention trials.
According to ACT-AD Executive Director Cynthia Bens, this year's meeting took a "back-to-basics" approach in the discussion of Alzheimer's disease, with presentations on what clinical trials have revealed, the changing conceptualization of the disease, and what experts are learning about AD genetics.
"Today's meeting offered an opportunity for attendees to frankly discuss what can be done to improve our prospects for treatment of Alzheimer's disease," said Bens. "We are very appreciative for the valuable insights shared by everyone."
The meeting brought together a distinguished group of presenters, including Rachelle Doody, M.D., Ph.D., Baylor College of Medicine, George Perry, Ph.D., The University of Texas San Antonio, and Bryan Traynor, M.D., Ph.D., MMSc, MRCPI, National Institute on Aging.
The meeting also included a panel of experts who discussed scientific and regulatory considerations for advancing pre-clinical Alzheimer’s disease therapeutic development.
Dr. Perry, who spoke on the changing conceptualization of AD, noted, "Today was remarkable. I came away encouraged from this meeting because of the honesty of the discussions regarding the status of clinical trials and their underlying biological and clinical endpoint assumptions. It is clear that we need to continue to make good progress to help families who are affected by Alzheimer’s disease and to build on the success of current approved therapeutics."
For future updates on the meeting, please go to the ACT-AD website.